Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 92

Results For "TD"

1163 News Found

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Biotech | January 29, 2022

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate

Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China


Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
News | January 26, 2022

Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.

Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021


JBCPL to acquire brands from Sanzyme for Rs 628 cr
News | January 26, 2022

JBCPL to acquire brands from Sanzyme for Rs 628 cr

Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise


FDC’s chooses UFlex’ Asepto holographic packaging for Electral
Packaging | January 25, 2022

FDC’s chooses UFlex’ Asepto holographic packaging for Electral

The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets
News | January 20, 2022

Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets

The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus


Green chemistry approaches to synthesis could make a big difference to pharma product outputs
News | January 20, 2022

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies